Unsure About ‘Breakthrough’-Worthiness? Talk To FDA First
Executive Summary
An early, informal conversation between a sponsor and the review division about the supportive data could help reduce the number of ‘breakthrough therapy’ designation requests that are ultimately denied, FDA and sponsors said.
You may also be interested in...
EMA Advice On PRIME: 'If You Don't Meet The Criteria, Don't Apply'
EMA officials expect to be "flooded" with applications for the new priority review scheme.
Following Through On Breakthrough: What’s Next For FDASIA Success?
FDA is building a case for enhanced funding to support the “Breakthrough” therapy program and at the same time is working to educate sponsors on how to use the new program effectively. The 21st Century Cures process floated a proposal for a new “Breakthrough” approval pathway – though that idea has been dropped. Still, it sets up an interesting discussion heading into 2017.
FDA Funding In Cures Bill Complicated By Metrics, Appropriators
But a Harvard researcher argues to improve drug development, basic research should receive more money because FDA review is not the problem.